Good news! In a just-published study, Jardiance (empagliflozin) for type 2 diabetes has been shown to reduce deaths from cardiovascular disease.
The results are impressive. Comparing Jardiance to a placebo, the study showed a 38% reduction in the risk of death from a cardiovascular cause (3.7% with Jardiance vs 5.9% with placebo). Jardiance was also shown to reduce the risk of any cardiovascular event (heart attack, stroke, or death) by 14%, and to reduce the risk of death from all causes by 32%.
You should know that the study, released September 17, 2015, was paid for by the manufacturers, Eli Lilly and Boehringer Ingelheim. The study involved 7,000 people with diabetes who were also at high risk for heart attack and stroke—which could mean the effects may not be as significant for people with lower risk.
Where doesn’t Jardiance seem to help?
It wasn’t shown to reduce the risk of heart attack all that much, and may actually increase the risk of stroke, though the increase wasn’t statistically significant in the study.
If Jardiance doesn’t reduce the risk of heart attack or stroke, how does it prevent deaths from cardiovascular causes?
The authors of the study aren’t sure, but there are a few ideas. It could be related to the way Jardiance reduces blood sugar, helping your body get rid of extra sugar through urination rather than letting it be absorbed by your kidneys. This could help lower blood pressure as well, by getting rid of extra liquid along with the sugar.
Jardiance may also cause weight loss, which can affect risk factors for cardiovascular disease, and help your overall health.
Want to know more?
You can find a more in-depth summary in these articles from the New York Times and ABC News. For cost information, simply check out GoodRx’s current prices.